SG11202005548WA - Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof - Google Patents

Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Info

Publication number
SG11202005548WA
SG11202005548WA SG11202005548WA SG11202005548WA SG11202005548WA SG 11202005548W A SG11202005548W A SG 11202005548WA SG 11202005548W A SG11202005548W A SG 11202005548WA SG 11202005548W A SG11202005548W A SG 11202005548WA SG 11202005548W A SG11202005548W A SG 11202005548WA
Authority
SG
Singapore
Prior art keywords
analogs
synthesis
compounds useful
prins reaction
halichondrin macrolides
Prior art date
Application number
SG11202005548WA
Inventor
Hyeong-Wook Choi
Francis G Fang
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11202005548WA publication Critical patent/SG11202005548WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11202005548WA 2018-01-03 2019-01-03 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof SG11202005548WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862613307P 2018-01-03 2018-01-03
PCT/US2019/012178 WO2019136145A1 (en) 2018-01-03 2019-01-03 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Publications (1)

Publication Number Publication Date
SG11202005548WA true SG11202005548WA (en) 2020-07-29

Family

ID=67143922

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005548WA SG11202005548WA (en) 2018-01-03 2019-01-03 Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Country Status (9)

Country Link
US (2) US11542269B2 (en)
EP (1) EP3737673B1 (en)
JP (1) JP7469226B2 (en)
KR (1) KR20200105877A (en)
CN (1) CN111868044A (en)
IL (1) IL275729B2 (en)
MX (2) MX2020006945A (en)
SG (1) SG11202005548WA (en)
WO (1) WO2019136145A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
SG11201603490TA (en) * 2013-11-04 2016-05-30 Eisai R&D Man Co Ltd Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
CN117024469A (en) 2015-05-07 2023-11-10 卫材R&D管理有限公司 Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments
SG11201806133UA (en) 2016-02-12 2018-08-30 Eisai R&D Man Co Ltd Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811671XA (en) 2016-06-30 2019-01-30 Eisai R&D Man Co Ltd Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2023144733A1 (en) * 2022-01-26 2023-08-03 Simon Fraser University Compounds and processes for the preparation of eribulin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107206A (en) 1974-04-08 1978-08-15 Akzona Incorporated Benzo-bicyclononene- derivatives
SU652180A1 (en) 1975-12-16 1979-03-15 Краснодарский политехнический институт Method of obtaining 1-(furyl-2')-2-(2-"formyl-furyl-5") ethylene and its methyl derivative as intermediate product for synthesis of furan-2,5-dicarboxylic acid
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (en) 1992-09-09 1995-09-01 Hoechst Ag
CA2264298A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Catalytic selective sulfonylation process
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP1087960B1 (en) 1998-06-17 2011-03-23 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DE10106647A1 (en) 2001-02-12 2002-08-22 Univ Hannover Ratjadon derivatives to inhibit cell growth
EP1771431A1 (en) 2004-06-03 2007-04-11 Eisai Co., Ltd. Intermediates for the preparation of halichondrin b
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
JP2009510005A (en) * 2005-09-26 2009-03-12 シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト Intramolecular Prince reaction and catalyst suitable for the reaction
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
US8119839B2 (en) 2007-07-20 2012-02-21 Yamada Apiculture Center, Inc. Carboxylic acid and antidepressant composition containing the same as active ingredient
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
RU2010118063A (en) 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) A NEW INTERMEDIATE COMPOUND FOR SYNTHESIS OF ANALOG OF HALICHONDRIN B AND A NEW DESULPHONILATION REACTION USED FOR OBTAINING AN INTERMEDIATE COMPOUND
SG189739A1 (en) 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
JP5371091B2 (en) 2009-01-23 2013-12-18 三菱レイヨン株式会社 Method for producing monosulfonic acid ester
SG10201500552PA (en) 2010-01-26 2015-03-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
WO2013142999A1 (en) 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
EP3016957A4 (en) 2013-07-03 2016-11-30 Alphora Res Inc Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
SG11201603490TA (en) 2013-11-04 2016-05-30 Eisai R&D Man Co Ltd Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
RU2676486C1 (en) 2013-12-06 2018-12-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Methods for synthesis of halichondrin b analogs
EP3191479B1 (en) 2014-09-09 2020-04-08 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
CN117024469A (en) * 2015-05-07 2023-11-10 卫材R&D管理有限公司 Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments
SG11201806133UA (en) 2016-02-12 2018-08-30 Eisai R&D Man Co Ltd Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811671XA (en) 2016-06-30 2019-01-30 Eisai R&D Man Co Ltd Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
US20180009825A1 (en) 2016-07-06 2018-01-11 Apicore Us Llc Methods of making eribulin mesylate
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
IL275729B2 (en) 2018-01-03 2023-09-01 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
IL275729B2 (en) 2023-09-01
US11542269B2 (en) 2023-01-03
JP7469226B2 (en) 2024-04-16
MX2020006945A (en) 2020-11-09
US20230151022A1 (en) 2023-05-18
EP3737673A4 (en) 2021-08-25
IL275729B1 (en) 2023-05-01
CN111868044A (en) 2020-10-30
RU2020125252A (en) 2022-02-03
IL275729A (en) 2020-08-31
US20200331928A1 (en) 2020-10-22
KR20200105877A (en) 2020-09-09
WO2019136145A1 (en) 2019-07-11
MX2022009886A (en) 2022-08-22
JP2021509665A (en) 2021-04-01
EP3737673B1 (en) 2024-03-06
EP3737673A1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
IL275729B1 (en) Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
IL288460A (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
IL288468A (en) Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
IL276376B (en) Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
IL281275B (en) Methods useful in the synthesis of halichondrin b analogs
IL271939A (en) Method for the preparation of synthesis gas
EP3160970A4 (en) Synthesis of halichondrin analogs and uses thereof
IL204791A0 (en) Intermediates and methods for the synthesis of halichondrin b analogs
ZA201908217B (en) Method for the preparation of synthesis gas
HK1217689A1 (en) Synthesis of calebin-a and its biologically active analogs calebin-a
HRP20190286T1 (en) Processes for the preparation of compounds, such as 3-arylbutanals, useful in the synthesis of medetomidine
EP3353153A4 (en) The total synthesis of glucosepane and compounds obtained therefrom
HRP20181918T1 (en) Process for the synthesis of benzazepine derivatives
IS2977B (en) Process for the preparation of intermediates useful in the synthesis of eluxadoline
LT3713939T (en) Improved process for the synthesis of linker-drug vc-seco
ME02213B (en) Process for the synthesis of derivatives of 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one and its
GB201616500D0 (en) Biological process for the conversion of xylans to xylitol